EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC) Meeting Abstract
| Authors: | Powles, T.; Van Der Heijden, M. S.; Loriot, Y.; Bedke, J.; Valderrama, B. P.; Iyer, G.; Kikuchi, E.; Hoffman-Censits, J.; Vulsteke, C.; Drakaki, A.; Rausch, S.; Arafat, W.; Park, S. H.; Swami, U.; Li, J. R.; Gorla, S. R.; Moreno, B. H.; Yu, X.; Lu, Y. T.; Gupta, S. |
| Abstract Title: | EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC) |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454740400044 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.664 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 664 -- Source: Wos |
